Analyst Estimates: Here's What Brokers Think Of Aemetis, Inc. (NASDAQ:AMTX) After Its Third-Quarter Report

In This Article:

Aemetis, Inc. (NASDAQ:AMTX) just released its third-quarter report and things are looking bullish. Results overall were credible, with revenues arriving 4.4% better than analyst forecasts at US$81m. Higher revenues also resulted in lower statutory losses, which were US$0.38 per share, some 4.4% smaller than the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

View our latest analysis for Aemetis

earnings-and-revenue-growth
NasdaqGM:AMTX Earnings and Revenue Growth November 15th 2024

Taking into account the latest results, the current consensus from Aemetis' six analysts is for revenues of US$466.8m in 2025. This would reflect a substantial 60% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 65% to US$0.68. Before this latest report, the consensus had been expecting revenues of US$467.1m and US$0.62 per share in losses. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a moderate increase in its losses per share forecasts.

As a result, there was no major change to the consensus price target of US$12.15, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Aemetis analyst has a price target of US$28.00 per share, while the most pessimistic values it at US$3.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Aemetis' growth to accelerate, with the forecast 46% annualised growth to the end of 2025 ranking favourably alongside historical growth of 6.8% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 3.1% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Aemetis to grow faster than the wider industry.

Waiting for permission
Allow microphone access to enable voice search

Try again.